zurück

Blinatumomab (new indication: B-precursor acute lymphoblastic leukaemia (ALL), high-risk first relapsed, Ph-, CD19+, patients aged ≥ 1 - < 18 years)

Subject:

  • Active Substance: Blinatumomab
  • Name: Blincyto®
  • Therapeutic area: B-precursor acute lymphoblastic leukaemia (ALL)
  • Pharmaceutical company: Amgen GmbH

Time table:

  • Start: 01.08.2021
  • Final decision by G-BA: 20.01.2022

Final decision:

  • Indication for a major additional benefit (orphan drug)